Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMTRACE.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs FEMTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estrogen receptor agonist; binds to estrogen receptors, modulating gene transcription and cellular proliferation in target tissues.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
1 to 2 mg orally once daily; for testosterone replacement in adult males, 2 to 4 mg orally once daily.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Terminal elimination half-life is approximately 12-14 hours, supporting once-daily dosing in clinical use.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Primarily renal; ~40% as unchanged drug and glucuronide conjugates. Biliary/fecal elimination is minor (~10-15%).
Category D/X
Category C
Estrogen
Estrogen